The desmoplastic small round cell tumor treatment market size has grown strongly in recent years. It will grow from $4.01 billion in 2025 to $4.35 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to limited treatment options for dsrct, reliance on conventional chemotherapy and surgery, low awareness of rare tumors, inadequate specialized oncology infrastructure, delayed diagnosis of dsrct.
The desmoplastic small round cell tumor treatment market size is expected to see strong growth in the next few years. It will grow to $5.92 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to development of targeted therapies and immunotherapies, integration of ai-driven diagnostics, rising clinical trials for dsrct, expansion of oncology clinics and ambulatory surgical centers, increasing healthcare funding for rare cancers. Major trends in the forecast period include rising adoption of multimodal cancer treatments, increasing focus on rare cancer research and clinical trials, growing investment in targeted therapies and immunotherapy, expansion of specialized oncology centers, enhanced patient support programs and post-treatment care.
The increasing emphasis on personalized medicine is anticipated to support the expansion of the desmoplastic small round cell tumor treatment market going forward. Personalized medicine involves tailoring healthcare approaches based on an individual’s genetic profile, lifestyle, and environmental factors, incorporating methods such as pharmacogenomics, targeted therapies, and gene editing. The heightened focus on personalized medicine is driven by advances in genomics, improved treatment outcomes, and the ability to deliver more precise and effective therapies. Personalized medicine enables more effective treatment of desmoplastic small round cell tumor (DSRCT) by aligning therapies with the tumor’s unique genetic and molecular characteristics, improving efficacy while reducing adverse effects. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare diseases in 2023, compared to six approvals in 2022. Consequently, the growing focus on personalized medicine is strengthening momentum in the DSRCT treatment market.
Growing investment in oncology research is expected to drive the growth of the desmoplastic small round cell tumor treatment market going forward. Investment in oncology research continues to rise due to increasing global cancer incidence, advancements in precision medicine, and the growing need for innovative therapies to improve patient outcomes. Oncology research supports the treatment of desmoplastic small round cell tumors by advancing understanding of tumor biology, enabling the development of targeted therapies and improved treatment protocols that enhance clinical outcomes. For example, in 2023, according to the Office for National Statistics, a UK-based government agency, the UK government’s net spending on research and development increased to £17.4 billion ($22.1 billion) in 2023 from £16.1 billion ($20.45 billion) in 2022, representing an 8.2% increase. Consequently, rising investment in oncology research is fueling growth in the desmoplastic small round cell tumor treatment market.
The increasing number of clinical trials is expected to propel the growth of the desmoplastic small round cell tumor treatment market going forward. Clinical trials involve human participants and are conducted to evaluate the safety and effectiveness of new medical treatments or procedures while generating scientific evidence for human use. The growth in clinical trials is driven by advances in medical research, rising disease burden, regulatory developments, globalization of clinical research, increased patient awareness and advocacy, industry competition, technological progress, and expanding funding opportunities. Clinical trials enable patient access to innovative therapies and support evaluation of new treatment approaches, improving outcomes and advancing the development of targeted and more effective therapies. For example, in December 2025, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported that the number of new industry-sponsored clinical trials initiated in the UK rose by 36% in 2024, increasing to 578 trials from 426 in 2023. As a result, the UK advanced to sixth place globally for phase III trial initiations in 2024, up from eighth place in 2023. Therefore, the growing number of clinical trials is driving the growth of the desmoplastic small round cell tumor treatment market.
Major companies operating in the desmoplastic small round cell tumor treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Fresenius Kabi AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., GlaxoSmithKline plc (GSK), Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Zymeworks Inc., Blueprint Medicines Corporation, MacroGenics Inc., Exelixis Inc.
North America was the largest region in the desmoplastic small round cell tumor treatment market in 2025. The regions covered in the desmoplastic small round cell tumor treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the desmoplastic small round cell tumor treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the dsrct treatment market by increasing the cost of imported targeted therapy drugs, monoclonal antibodies, and immunotherapy agents. Segments such as immunotherapy and advanced chemotherapeutic drugs are most affected, with regions including north america and europe facing higher import duties. This has led to elevated treatment costs and supply chain adjustments. However, tariffs have also encouraged local manufacturing of therapies and investment in domestic research, which may enhance long-term accessibility and innovation in dsrct treatments.
The desmoplastic small round cell tumor treatment market research report is one of a series of new reports that provides desmoplastic small round cell tumor treatment market statistics, including desmoplastic small round cell tumor treatment industry global market size, regional shares, competitors with a desmoplastic small round cell tumor treatment market share, detailed desmoplastic small round cell tumor treatment market segments, market trends and opportunities, and any further data you may need to thrive in the desmoplastic small round cell tumor treatment industry. This desmoplastic small round cell tumor treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Desmoplastic small round cell tumor (DSRCT) treatment involves therapies such as surgery, chemotherapy, and radiation aimed at controlling this rare, aggressive cancer and slowing its spread, mainly in the abdomen. These treatments can help shrink tumors, improve survival, and enhance quality of life.
The major treatment types in the desmoplastic small round cell tumor market include immunotherapy, surgical procedures, chemotherapy, and radiotherapy. Immunotherapy is a treatment approach that utilizes the body’s immune system to combat diseases, especially cancer. The different drug classes involved include cytotoxic agents, targeted therapies, and immunomodulators, and the primary end users include hospitals, oncology clinics, and ambulatory surgical centers.
The desmoplastic small round cell tumor treatment market includes revenues earned by entities by providing services such as immunotherapy, diagnostic imaging, and post treatment care, including rehabilitation and follow up monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The desmoplastic small round cell tumor treatment market size is expected to see strong growth in the next few years. It will grow to $5.92 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to development of targeted therapies and immunotherapies, integration of ai-driven diagnostics, rising clinical trials for dsrct, expansion of oncology clinics and ambulatory surgical centers, increasing healthcare funding for rare cancers. Major trends in the forecast period include rising adoption of multimodal cancer treatments, increasing focus on rare cancer research and clinical trials, growing investment in targeted therapies and immunotherapy, expansion of specialized oncology centers, enhanced patient support programs and post-treatment care.
The increasing emphasis on personalized medicine is anticipated to support the expansion of the desmoplastic small round cell tumor treatment market going forward. Personalized medicine involves tailoring healthcare approaches based on an individual’s genetic profile, lifestyle, and environmental factors, incorporating methods such as pharmacogenomics, targeted therapies, and gene editing. The heightened focus on personalized medicine is driven by advances in genomics, improved treatment outcomes, and the ability to deliver more precise and effective therapies. Personalized medicine enables more effective treatment of desmoplastic small round cell tumor (DSRCT) by aligning therapies with the tumor’s unique genetic and molecular characteristics, improving efficacy while reducing adverse effects. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare diseases in 2023, compared to six approvals in 2022. Consequently, the growing focus on personalized medicine is strengthening momentum in the DSRCT treatment market.
Growing investment in oncology research is expected to drive the growth of the desmoplastic small round cell tumor treatment market going forward. Investment in oncology research continues to rise due to increasing global cancer incidence, advancements in precision medicine, and the growing need for innovative therapies to improve patient outcomes. Oncology research supports the treatment of desmoplastic small round cell tumors by advancing understanding of tumor biology, enabling the development of targeted therapies and improved treatment protocols that enhance clinical outcomes. For example, in 2023, according to the Office for National Statistics, a UK-based government agency, the UK government’s net spending on research and development increased to £17.4 billion ($22.1 billion) in 2023 from £16.1 billion ($20.45 billion) in 2022, representing an 8.2% increase. Consequently, rising investment in oncology research is fueling growth in the desmoplastic small round cell tumor treatment market.
The increasing number of clinical trials is expected to propel the growth of the desmoplastic small round cell tumor treatment market going forward. Clinical trials involve human participants and are conducted to evaluate the safety and effectiveness of new medical treatments or procedures while generating scientific evidence for human use. The growth in clinical trials is driven by advances in medical research, rising disease burden, regulatory developments, globalization of clinical research, increased patient awareness and advocacy, industry competition, technological progress, and expanding funding opportunities. Clinical trials enable patient access to innovative therapies and support evaluation of new treatment approaches, improving outcomes and advancing the development of targeted and more effective therapies. For example, in December 2025, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported that the number of new industry-sponsored clinical trials initiated in the UK rose by 36% in 2024, increasing to 578 trials from 426 in 2023. As a result, the UK advanced to sixth place globally for phase III trial initiations in 2024, up from eighth place in 2023. Therefore, the growing number of clinical trials is driving the growth of the desmoplastic small round cell tumor treatment market.
Major companies operating in the desmoplastic small round cell tumor treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Fresenius Kabi AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., GlaxoSmithKline plc (GSK), Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Zymeworks Inc., Blueprint Medicines Corporation, MacroGenics Inc., Exelixis Inc.
North America was the largest region in the desmoplastic small round cell tumor treatment market in 2025. The regions covered in the desmoplastic small round cell tumor treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the desmoplastic small round cell tumor treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the dsrct treatment market by increasing the cost of imported targeted therapy drugs, monoclonal antibodies, and immunotherapy agents. Segments such as immunotherapy and advanced chemotherapeutic drugs are most affected, with regions including north america and europe facing higher import duties. This has led to elevated treatment costs and supply chain adjustments. However, tariffs have also encouraged local manufacturing of therapies and investment in domestic research, which may enhance long-term accessibility and innovation in dsrct treatments.
The desmoplastic small round cell tumor treatment market research report is one of a series of new reports that provides desmoplastic small round cell tumor treatment market statistics, including desmoplastic small round cell tumor treatment industry global market size, regional shares, competitors with a desmoplastic small round cell tumor treatment market share, detailed desmoplastic small round cell tumor treatment market segments, market trends and opportunities, and any further data you may need to thrive in the desmoplastic small round cell tumor treatment industry. This desmoplastic small round cell tumor treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Desmoplastic small round cell tumor (DSRCT) treatment involves therapies such as surgery, chemotherapy, and radiation aimed at controlling this rare, aggressive cancer and slowing its spread, mainly in the abdomen. These treatments can help shrink tumors, improve survival, and enhance quality of life.
The major treatment types in the desmoplastic small round cell tumor market include immunotherapy, surgical procedures, chemotherapy, and radiotherapy. Immunotherapy is a treatment approach that utilizes the body’s immune system to combat diseases, especially cancer. The different drug classes involved include cytotoxic agents, targeted therapies, and immunomodulators, and the primary end users include hospitals, oncology clinics, and ambulatory surgical centers.
The desmoplastic small round cell tumor treatment market includes revenues earned by entities by providing services such as immunotherapy, diagnostic imaging, and post treatment care, including rehabilitation and follow up monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Desmoplastic Small Round Cell Tumor Treatment Market Characteristics
3. Desmoplastic Small Round Cell Tumor Treatment Market Supply Chain Analysis
4. Global Desmoplastic Small Round Cell Tumor Treatment Market Trends and Strategies
5. Desmoplastic Small Round Cell Tumor Treatment Market Analysis of End Use Industries
7. Global Desmoplastic Small Round Cell Tumor Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Desmoplastic Small Round Cell Tumor Treatment Total Addressable Market (TAM) Analysis for the Market
9. Desmoplastic Small Round Cell Tumor Treatment Market Segmentation
10. Desmoplastic Small Round Cell Tumor Treatment Market Regional and Country Analysis
11. Asia-Pacific Desmoplastic Small Round Cell Tumor Treatment Market
12. China Desmoplastic Small Round Cell Tumor Treatment Market
13. India Desmoplastic Small Round Cell Tumor Treatment Market
14. Japan Desmoplastic Small Round Cell Tumor Treatment Market
15. Australia Desmoplastic Small Round Cell Tumor Treatment Market
16. Indonesia Desmoplastic Small Round Cell Tumor Treatment Market
17. South Korea Desmoplastic Small Round Cell Tumor Treatment Market
18. Taiwan Desmoplastic Small Round Cell Tumor Treatment Market
19. South East Asia Desmoplastic Small Round Cell Tumor Treatment Market
20. Western Europe Desmoplastic Small Round Cell Tumor Treatment Market
21. UK Desmoplastic Small Round Cell Tumor Treatment Market
22. Germany Desmoplastic Small Round Cell Tumor Treatment Market
23. France Desmoplastic Small Round Cell Tumor Treatment Market
24. Italy Desmoplastic Small Round Cell Tumor Treatment Market
25. Spain Desmoplastic Small Round Cell Tumor Treatment Market
26. Eastern Europe Desmoplastic Small Round Cell Tumor Treatment Market
27. Russia Desmoplastic Small Round Cell Tumor Treatment Market
28. North America Desmoplastic Small Round Cell Tumor Treatment Market
29. USA Desmoplastic Small Round Cell Tumor Treatment Market
30. Canada Desmoplastic Small Round Cell Tumor Treatment Market
31. South America Desmoplastic Small Round Cell Tumor Treatment Market
32. Brazil Desmoplastic Small Round Cell Tumor Treatment Market
33. Middle East Desmoplastic Small Round Cell Tumor Treatment Market
34. Africa Desmoplastic Small Round Cell Tumor Treatment Market
36. Desmoplastic Small Round Cell Tumor Treatment Market Competitive Landscape and Company Profiles
37. Desmoplastic Small Round Cell Tumor Treatment Market Other Major and Innovative Companies
40. Desmoplastic Small Round Cell Tumor Treatment Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Desmoplastic Small Round Cell Tumor Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses desmoplastic small round cell tumor treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for desmoplastic small round cell tumor treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The desmoplastic small round cell tumor treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Immunotherapy; Surgical Operation; Chemotherapy; Radiotherapy2) By Drug Class: Cytotoxic Agents; Targeted Therapies; Immunomodulators
3) By End User: Hospitals; Oncology Clinics; Ambulatory Surgical Centers
Subsegments:
1) By Immunotherapy: Checkpoint Inhibitors; CAR T-Cell Therapy; Monoclonal Antibodies; Immune Modulators2) By Surgical Operation: Tumor Resection; Debulking Surgery; Laparoscopic Surgery
3) By Chemotherapy: Neoadjuvant Chemotherapy; Adjuvant Chemotherapy; Targeted Therapy Agents
4) By Radiotherapy: External Beam Radiation Therapy (EBRT); Brachytherapy; Stereotactic Radiosurgery (SRS)
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; Fresenius Kabi AG; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Boehringer Ingelheim International GmbH; Gilead Sciences Inc.; Amgen Inc.; GlaxoSmithKline plc (GSK); Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Aurobindo Pharma Limited; Hikma Pharmaceuticals PLC; Zymeworks Inc.; Blueprint Medicines Corporation; MacroGenics Inc.; Exelixis Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Desmoplastic Small Round Cell Tumor Treatment market report include:- Pfizer Inc.
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Novartis AG
- Fresenius Kabi AG
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Gilead Sciences Inc.
- Amgen Inc.
- GlaxoSmithKline plc (GSK)
- Teva Pharmaceutical Industries Ltd.
- Regeneron Pharmaceuticals Inc.
- Aurobindo Pharma Limited
- Hikma Pharmaceuticals PLC
- Zymeworks Inc.
- Blueprint Medicines Corporation
- MacroGenics Inc.
- Exelixis Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 4.35 Billion |
| Forecasted Market Value ( USD | $ 5.92 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
